NRXP earnings date and last-quarter result: next report 2026-08-17, last quarter beat, P/E -3.49. Updated 2026-07-23.
NRx Pharmaceuticals (NRXP) Research Hub
NRx Pharmaceuticals (NRXP) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 2.55 USD (+2.41%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -3.49, market cap 0.08B. This hub links to the full technical, earnings and options research available for NRXP.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 2.55 USD (+2.41%) |
| 52-week range | 2.24 USD – 4.64 USD |
| Trend regime | Range |
| 14-day RSI | 30.7 (Bearish) |
| Trailing P/E | -3.49 |
| Market cap | 0.08B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-17 |
Available research for NRXP
Covered Call on NRXP: how it works, illustrative setup around the real 2.55 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on NRXP: how it works, illustrative setup around the real 2.55 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on NRXP: how it works, illustrative setup around the real 2.55 USD price, max profit/loss, breakeven and when to use it. Educational.
NRXP technical analysis: range, last 2.55 USD, RSI 30.7, 52w range 2.24 USD–4.64 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is NRXP in?
NRx Pharmaceuticals (NRXP) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is NRXP in an uptrend or downtrend?
As of 2026-10-26, NRXP is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is NRXP's trailing P/E ratio?
NRXP's trailing P/E is -3.49, with a market cap of 0.08B. See the earnings research page for full valuation detail.
When does NRXP next report earnings?
NRXP is next scheduled to report earnings on 2026-08-17.